

Supplementary File 3

Only extremely limited data are available on the specific use of selective estrogen receptor modulators (ie, tamoxifen, raloxifene) in patients with *BRCA1/2* mutations. In NSABP-P1 study, tamoxifen reduced the risk for breast cancer by 50% in 11 *BRCA2* mutation carriers, while failed to reduce the risk for breast cancer in 8 *BRCA1* mutation carriers.^[4] There is no evidence that aromatase inhibitors can reduce the risk of breast cancer in *BRCA1/2* mutation carriers.

1. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, *et al.* National Surgical Adjuvant Breast and Bowel Project. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001;286:2251-6. doi: 10.1001/jama.286.18.2251.